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An autosomal-recessive syndrome of biﬁd nose and anorectal and renal anomalies (BNAR) was previously reported in a consanguineous
Egyptian sibship. Here, we report the results of linkage analysis, on this family and on two other families with a similar phenotype,
which identiﬁed a shared region of homozygosity on chromosome 9p22.2-p23. Candidate-gene analysis revealed homozygous frame-
shift and missense mutations in FREM1, which encodes an extracellular matrix component of basement membranes. In situ hybridiza-
tion experiments demonstrated gene expression of Frem1 in the midline of E11.5 mouse embryos, in agreement with the observed cleft
nose phenotype of our patients. FREM1 is part of a ternary complex that includes FRAS1 and FREM2, and mutations of the latter two
genes have been reported to cause Fraser syndrome in mice and humans. The phenotypic variability previously reported for different
Frem1 mouse mutants suggests that the apparently distinct phenotype of BNAR in humans may represent a previously unrecognized
variant of Fraser syndrome.In 2002, Al-Gazali et al. reported a second-cousin consan-
guineous Egyptian family in which four siblings had biﬁd
nose associated with anorectal and renal abnormalities
(BNAR [MIM 608980]).1 One of the children was born
with bilateral renal agenesis and died within the ﬁrst
hour of life. The surviving three presented with unilateral
renal agenesis, low-pitched crying, short and thick oral
frenula, incurved ﬁfth toe, anteriorly placed anus, and
stenosis of the anal opening. Importantly, the biﬁd nose
with bulbous nasal tip was not associated with hypertelor-
ism. This therefore represented an apparently distinct
autosomal-recessive phenotype. We have also observed
this rare disorder in two consanguineous families of
Afghani and Pakistani origin (Figure 1A), in which the
phenotype is essentially similar although kidney involve-
ment is more variable (Table 1).
The apparent autosomal-recessive mode of inheritance
suggested that autozygosity mapping would determine
the disease locus in these consanguineous families. After
obtaining written and informed consent from all patients
or their legal guardians (in accordance with a protocol
approved by the King Faisal Specialist Hospital institu-
tional review board, protocol no. 2080006), we imple-
mented genome-wide multipoint parametric linkage anal-
ysis, using the Affymetrix 250K StyI GeneChip platform
(Affymetrix, Santa Clara, CA, USA). Resulting genotyping
data were analyzed with the EasyLinkage software package,
assuming fully penetrant autosomal-recessive inheritance
and a disease allele frequency of 0.0001, with a consan-
guinity loop utilized for each family. Analysis of all414 The American Journal of Human Genetics 85, 414–418, Septemsurviving affected individuals yielded a maximum LOD
score of 6.62 between SNP markers rs10124106 and
rs10963391, a 4.4 Mb interval on 9p22.2–p23 encompass-
ing a total of 28 annotated genes (Figure S1, available on-
line). This was in agreement with data obtained with the
use of microsatellite markers and signiﬁed that a single
locus, but on different haplotypes, was the likely cause of
the syndrome in all three families. Candidate-gene selec-
tion was prioritized according to expression levels in the
developing kidney and assessment of the mouse knockout
phenotype, if known. The most promising candidate gene
that met our criteria was FRAS1-related extracellular matrix
protein 1 (FREM1 [MIM 608944]), which encodes a base-
ment membrane protein. Deﬁciency of the orthologous
Frem1 in mouse results in a phenotype that includes renal
agenesis.2,3 Primers were therefore designed to ﬂank all
known FREM1 exons, as identiﬁed on the UCSC and
Ensembl websites, and were directly sequenced with the
dideoxy chain-termination method (Amersham ET Dye
Termination Sequencing Kit). Samples were processed on
a MegaBACE 1000 (Molecular Dynamics, Sunnyvale, CA,
USA).
Sequence analysis with SeqMan II (DNASTAR, Madison,
WI, USA) revealed a single basepair (bp) deletion in
exon 17 of FREM1 in the Egyptian family (c.2721delG;
NM_144966), predicting a frameshift at amino acid 908
and a premature truncation 17 residues downstream
(p.V908SfsX17; Figure 1B). In the Afghani sibship, we iden-
tiﬁed a transition in exon 12, predicted to cause an Arg-to-
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Figure 1. Mutations in FREM1 are Responsible for Bifid Nose, Renal Agenesis, and Anorectal Malformations Syndrome
(A) A representative BNAR patient from each of the two new families described in this report (note the discoloration at the tip of the nose
that was observed in a subset of patients).
(B) Chromatograms of the three mutations showing control sequences on top, with the mutation sites denoted by asterisks.
(C) Multiple sequence alignments of the FREM1 protein reveal that the amino acids perturbed by the twomissense mutations are highly
conserved across species.
(D) Schematic of the FREM1 protein indicating conserved domains and the location of mutations given in (B) (arrows), as well as trun-
cating mutations that have been reported in mice (arrowheads). CSPG, chondroitin sulfate proteoglycan; LecC, type C lectin-like
domain.family harbored a different transition in exon 25, which
predicted a Gly-to-Ser alteration (c.4318G>A [p.G1440S])
(Figure 1B). All mutations segregated with the disease state
and were conﬁrmed via bidirectional sequencing, and all
patients were homozygous for their respective mutations.
To validate the two missense mutations, we examined
121 Afghani and 97 Indian subcontinental normal control
individuals, respectively. No trace of either mutation was
found, indicating that these sequence variants are not
common polymorphisms within the two populations.
Furthermore, protein sequence alignment of FREM1 ortho-
logs demonstrated that the affected residues are highly
conserved across species, from human to fugu and for
the G1440S alteration, even down to the Florida lancelet
and the Ciona intestinalis sea squirt (Figure 1C), lending
further credence to the pathogenicity of these amino
acid substitutions.
Frem1 is part of a ternary complex that includes two
other extracellular matrix proteins, Fras1 (MIM 607830)The Americanand Frem2 (MIM 608945).2 To a large extent, these three
proteins are functionally interdependent. They exhibit
strict colocalization in the epithelial basement membrane
of several organs within the developing mouse,2,4,5 and
although one Frem1mutant did display normal Fras1 local-
ization,3 compromising the expression of any one of these
three proteins generally leads to reduced deposition of the
other two.2,5,6 Indeed, mutations of either FRAS1 or FREM2
lead to Fraser syndrome (FS [MIM 219000]),7–9 an auto-
somal-recessive condition characterized most notably by
cryptophthalmos (due to failure of palpebral ﬁssure devel-
opment) in ~90% of human cases, syndactyly in ~60% of
cases, as well as renal agenesis and abnormal or ambiguous
genitalia (Table 1).10
A set of four spontaneousmousemutants, known as bleb
mutants, each mapping to a different chromosome, have
long been considered to represent mouse models of FS.11
The hallmark of these bleb mutants is the formation of
subepidermal blisters, appearing at midgestation, whichJournal of Human Genetics 85, 414–418, September 11, 2009 415
Table 1. Comparison of Frequency of Key Clinical Features between BNAR and Fraser Syndrome
BNAR Fraser Syndrome
c.2721delG c.1945C>T c.4318G>A Overall Overall
Cryptophthalmos 0/4 0/3 0/2 0% 85–88%
Syndactyly 0/3 0/3 0/3 0% 62–95%
Abnormal genitalia 0/3 0/3 0/3 0% 40–66%
Biﬁd nose 4/4 3/3 2/2 100% 15%
Ear malformation 0/3 0/3 0/3 0% 59–75%
Airway malformation 0/3 0/3 2/2 22% 31–58%
Anorectal malformation 2/4 0/3 0/2 22% 16–32%
Renal agenesis 4/4 1/3 1/2 66% 45–77%
Fraser syndrome data are based on Slavotinek and Tifft10 and van Haelst et al.21then become hemorrhagic, possibly as a result of in utero
friction.3,9,12 Although this often leads to embryonic
lethality, mice that are born at term do not display further
blistering, an indication that this defect is temporally
restricted.3,7,8 In addition, most bleb mice also exhibit
cryptophthalmos, syndactyly, and renal malformation,
traits that link them to human FS.11 The classic bleb
mutants blebbed, myelencephalic blebs, and eye blebs are
now known to harbor mutations in, respectively, Fras1,
Frem2, and Grip1 (which encodes a scaffolding protein
required for basolateral targeting of Fras1 and Frem2)
(MIM 604597).7–9,13 The fourth classic mutant, head blebs
(heb), though it was similarly found to contain a truncating
mutation in Frem1,3 bears a signiﬁcantly milder pheno-
type. None of the homozygous heb embryos or adults in
the original report was found to exhibit cryptophthalmos,
a characteristic ﬁnding in the other bleb mutants. Syndac-
tyly also was not present, although polydactyly was.14 In
fact, 97% of E17 embryos demonstrated an ‘‘open eyelids’’
phenotype that is in marked contrast to Fras1/ mice, for
example, in which adults were reported to show 20% bilat-
eral and 75% unilateral cryptophthalmos.9
In the course of normal mammalian development, the
eyelids expand across the corneal surface, temporarily
fusing then subsequently reopening. In mice, this tempo-
rary closure transpires between E15.5 and E16.5 and
remains in place until roughly two weeks after birth,
when complete separation occurs.15 Due to the failure of
eyelid fusion in heb, the eyes suffer from in utero mechan-
ical damage and reduced eyeball growth. As adults, these
mice keep their eyelids closed as a means of coping with
their atrophic eyes.14 The temporary epithelial fusion of
both halves of the eyelid involves participation of cells of
the periderm layer.16 Interestingly, whereas Fras1 remains
restricted to the basement membrane of the advancing
eyelid, Frem1 is also found in the rounded periderm cells
that lie along the plane of eyelid fusion, which may help
explain the unique ‘‘open eyes at birth’’ phenotype of
the heb mutants.5416 The American Journal of Human Genetics 85, 414–418, SeptemTwo further Frem1 mutants have also been described.
The ﬁrst, labeled bat, also displays an ‘‘open eyes at birth’’
phenotype, though cryptophthalmos was also observed.3
In addition, 20% of homozygous bat mutants revealed
unilateral renal agenesis, whereas the original hebmutants
were described as having normal kidneys.14 Occasional
syndactyly was also reported in bat. The second, Qbrick/
Frem1/, exhibits cryptophthalmos, syndactyly, and renal
agenesis.2 This phenotypic variability may be due to differ-
ences in genetic background (which in the case of bat, for
example, was shown to signiﬁcantly modulate phenotype
penetrance),3 or they may be caused by allelic differences
between the three mutants. This latter possibility is further
supported by the fact that although both bat and Qbrick/
Frem1/ utilize C57BL/6 mice, the deposition of Fras1 in
the embryonic epidermis is unaffected in bat, whereas in
Qbrick/Frem1/ the deposition is substantially reduced.
Both human FREM1 and its mouse ortholog are com-
posed of a putative signal sequence, 12 chondroitin sulfate
proteoglycan (CSPG) repeats,17 a Calx-b domain, and a
C-terminal type C lectin-like domain (Figure 1D). On the
basis of previous delineation of the CSPG repeats,18 the
Afghani missense mutation lies in the fourth CSPG repeat,
the truncating frameshift mutation in the sixth, and the
Pakistani missense mutation in the tenth repeat. The orig-
inal mouse heb mutant incorporates a LINE1 insertion in
the seventh CSPG repeat, and bat contains a donor splice
site mutation leading to frameshift in the twelfth repeat.3
Qbrick/Frem1/ knocks out the entire gene by replacing
the initiation codon.2 Correlating our patient phenotypes
to the mouse models on the basis of the site of mutation is
not straightforward. BNAR appears to be a mixture of the
heb’s lack of cryptophthalmos and the bat and Qbrick/
Frem1/ mutants’ presence of renal agenesis.
Temporal and spatial expression data have been pub-
lished on Frem1 previously.3 However, the expression
pattern of this gene in midline is generally lacking. There-
fore, and given the highly penetrant biﬁd nose component
of BNAR, we decided to assay Frem1 expression in theber 11, 2009
Figure 2. Frem1 Is Expressed in the
Developing Nose
(A) RNA in situ hybridization experiment
showing strong expression in the snout
region of an E11.5 mouse.
(B) Inferior view along the plane of the
dotted line in (A) showing strong expres-
sion at midline (x8).
(C and D) Section of (A) showing strong
expression at the area of fusion of the
two medial nasal processes (x20) (C), and
the sense control for comparison (D).developing nose of E11.5 whole-mount embryos. Two
Frem1 probes were utilized, one spanning c.4446–48523
and the other spanning c.2070–2854 (NM_144966). SP6-
and T7-tagged primers were used for generating, respec-
tively, sense and antisense digoxygenin-labeled RNA
probes with the MaxiScript Kit (Ambion, Austin, TX,
USA) and Roche’s DIG RNA Labeling Mix (Indianapolis,
IN, USA). Embryos were permeabilized with proteinase K
(10 mg/ml) at 37C for 4 min, and in situ hybridization
was performed with the InsituPro VSi (Intavis AG, Koeln,
Germany) in accordance with a manufacturer-recommen-
ded protocol. Both antisense probes demonstrated strong
and speciﬁc staining in the snout, as well as in the midline,
where the two medial nasal processes fuse (Figures 2A and
2B). After in situ hybridization, examination of 5 mm
sections of parafﬁn-embedded embryos revealed that
Frem1 expression in the developing nose was mainly in
the epithelial-mesenchymal transitional region at the
midline (Figures 2C and 2D). Localization of Frem1 in
this area, coupled with the consistent biﬁd nose pheno-
type of our patients, strongly argues for an important
role by Frem1 in the fusion of the medial nasal processes
during gestation.
Among the Fras1/Frem proteins, Frem1 is unique in
several aspects. It is expressed predominantly from the
underlying mesenchyme, although to a lesser extent also
from the epithelia,3,5 and is targeted with the use of
a Grip1-independent pathway. Fras1 and Frem2 are strictly
secreted from the epiderm and require Grip1 for correct
basolateral targeting.2,13 Although all three overlap in the
basement membrane, Frem1 expression in the ocular
region is slightly delayed in comparison to the others.4
Ablation of Fras1 or Frem2 causes complete loss of the
ternary complex, but in the bat mutant of Frem1, deposi-
tion of Fras1 is unaffected,3 whereas in Qbrick/Frem1/,
only residual levels of Fras1 and Frem2 are detectable in
the skin basement membrane.2 Even more intriguing is
the supplementary role of Frem1 in periderm cells, a role
that is ﬁrst apparent at E16.5 and becomes almost exclu-
sive by E18.5. Notably, in the adult mouse, Frem1 is not
required for complex stabilization, because, unlike Fras1The Americanand Frem2, no appreciable levels of Frem1 are present in
the P30 kidney, gut, testes, or esophagus.19 Finally, unlike
the phenotypic consistency observed in mice bearing
Fras1, Frem2, and Grip1mutations, the range of phenotype
is considerably wider with Frem1mutants. Reassessment of
the literature demonstrates that at least some of these
mutants fall outside the scope of FS. These observations
may explain why our patient phenotype differs from that
of classic FS, given that we have shown in this study that
nonsense and missense mutations in FREM1 cause BNAR,
a disorder with features that are both overlapping and
distinct from FS. Previous studies have failed to identify
pathogenic FREM1 mutations in patients with classic
FS,20 and this suggests that FREM1 mutations are exceed-
ingly rare in this context or that they lead to BNAR or to
other phenotypes that are not recognized clinically as FS.
On the other hand, the remarkable phenotypic variability
observed inmurine Frem1mutants argues for the classiﬁca-
tion of BNAR as an atypical FS subtype. Future studies on
the genetics of FS should include ‘‘atypical’’ cases for exam-
ination of the contribution of FREM1 to the genetics of this
syndrome.
In summary, this report further underscores the differ-
ences between Frem1 and Fras1/Frem2 and establishes,
for the ﬁrst time to our knowledge, a role for FREM1 in
human craniofacial and renal development.
Supplemental Data
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